When Schering-Plough and Merck announced Nov. 19 they had been advised to change the scientific goal of a long-delayed clinical trial comparing the effectiveness of their blockbuster cholesterol Vytorin to a generic, the decision drew press scrutiny, criticism and a Congressional investigation.